




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b>  <b>A61N 1/368</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/58191</b>  <b>(43) International Publication Date:</b> 18 November 1999 (18.11.99)
<b>(21) International Application Number:</b> PCT/US99/10142 <b>(22) International Filing Date:</b> 7 May 1999 (07.05.99)  <b>(30) Priority Data:</b> 60/084,704      8 May 1998 (08.05.98)      US 09/075,278      8 May 1998 (08.05.98)      US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US      09/075,278 (CIP) Filed on      8 May 1998 (08.05.98)  <b>(71) Applicant (for all designated States except US):</b> CARDIAC PACEMAKERS, INC. [US/US]; 4100 Hamline Avenue North, St. Paul, MN 55112 (US).  <b>(71)(72) Applicants and Inventors:</b> DING, Jiang [CN/US]; 555 Harriet Avenue #916, Shoreview, MN 55126 (US). YU, Yinghong [CN/US]; 2926 Walter Street, Maplewood, MN 55109 (US). KRAMER, Andrew, P. [US/US]; 418 South Sixth Street, Stillwater, MN 55082 (US). SPINELLI, Julio [AR/US]; 5612 Chatsworth Street, Shoreview, MN 55126 (US).	<b>(74) Agent:</b> VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).  <b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	

(54) Title: CARDIAC PACING USING ADJUSTABLE ATRIO-VENTRICULAR DELAYS



## (57) Abstract

A pacing system for providing optimal hemodynamic cardiac function for parameters such as contractility (peak left ventricle pressure change during systole or  $LV+dp/dt$ ), or stroke volume (aortic pulse pressure) using system for calculating atrio-ventricular delays for optimal timing of a ventricular pacing pulse. The system providing an option for near optimal pacing of multiple hemodynamic parameters. The system deriving the proper timing using electrical or mechanical events having a predictable relationship with an optimal ventricular pacing timing signal.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## CARDIAC PACING USING ADJUSTABLE ATRIO-VENTRICULAR DELAYS

### Field of the Invention

The present invention relates generally to a method and apparatus for cardiac pacing and, in particular, to a pacing system providing adjustable atrio-ventricular time delays to improve different heart performance parameters.

5 This patent application claims the benefit of earlier-filed U.S. Provisional Patent Application Serial No. 60/084,703, filed May 8, 1998 and U.S. Patent Application Serial No. 09/075,278, filed May 8, 1998 according to 35 U.S.C. Section 119(e).

### Background of the Invention

10 The heart is the center of the circulatory system. It is an organ which performs two major pumping functions and may be divided into right and left heart "pumps." The left heart pump draws oxygenated blood from the lungs and pumps it to the organs of the body. The right heart pump draws blood from the body organs and pumps it into the lungs. For a human heart, the right heart pump is on a  
15 patient's right side and the left heart pump is on the patient's left side. Figures in this document, such as FIG. 1, show a "top" view of the heart, which is the view that a physician observes during open heart surgery. Therefore, the left heart pump is on the right hand side of the FIG. 1 and the right heart pump is on the left hand side of FIG. 1. Each heart pump includes an upper chamber called an atrium and a lower  
20 chamber called a ventricle. The left heart pump therefore contains a left atrium (LA) and a left ventricle (LV), separated by a valve called the mitral valve. The right heart pump contains a right atrium (RA) and a right ventricle (RV), separated by a valve called the tricuspid valve.

The blood flows in the circulatory system in the following path: from  
25 the peripheral venous system (blood which has transferred through the body organs) to the RA, from the RA to the RV through the tricuspid valve, from RV to the pulmonary artery through the pulmonary valve, to the lungs. Oxygenated blood from the lungs is drawn from the pulmonary vein to the LA, from the LA to the LV through the mitral valve, and finally, from the LV to the peripheral arterial system  
30 (transferring blood to the organs of the body) through the aortic valve.

Normally, the heart pumps operate in synchrony and ensure the proper pumping action to provide oxygenated blood from the lungs to the organs of the body. A normal heart provides this synchrony by a complex conduction system which propagates electrical pulses to the heart muscle tissue to perform the  
5 necessary atrial and ventricular contractions. A heartbeat is the result of a regular train of electrical pulses to the proper portions of the heart to provide rhythmic heart pumping. The heart muscle provides pumping by the contraction of muscle tissue upon receipt of an electrical signal, and the pumping action is made possible through a system of heart valves which enable blood flow in a single direction. Thus, the  
10 heart includes a complex electrical and mechanical network.

To pump blood through the circulatory system, a beating heart performs a cardiac cycle. A cardiac cycle consists of a systolic phase and a diastolic phase. During systole, the ventricular muscle cells contract to pump blood through both the pulmonary circulation and the systemic circulation. During diastole, the  
15 ventricular muscle cells relax, which causes pressure in the ventricles to fall below that in the atria, and the ventricles begin to be refilled with blood.

In normal condition, the cardiac pumping is highly efficient. One aspect of this high efficiency is due to sequential atrio-ventricular contraction. Near the end of diastole, the atria contract, causing an extra amount of blood to be forced  
20 into the ventricles. Thus, the ventricles have more blood (preload) to pump out during next systole. Another aspect of this high efficiency in blood pumping is contributed from a network or fast ventricular conduction system. As shown in FIG. 1, the system includes right and left bundle branches of conductive tissues that extend from the Bundle of His and the massive network of fast conducting Purkinje  
25 fibers that cover most of the endocardial surface of the ventricles. Electrical signals coming from the atrium are relayed to the Purkinje fibers through the bundle branches, and to the different regions of the ventricles by the Purkinje fiber network. Therefore the entire ventricular muscle cells can contract synchronously during systole. This synchronized contraction enhances the strength of the pumping power.

30 To assess the cardiac function, it is important to examine the LV systolic performance which directly determines the ability of the heart to pump blood through the systemic circulation. There are multiple ways to assess the performance of the heart. One way is to examine how well the LV contracts in order

to determine the effectiveness of the LV as a pump. As can be seen from FIG. 2, the LV starts to contract after an electrical signal propagating down the left bundle branches stimulates muscle cells of septal wall M and lateral wall N. In FIG. 3, the walls M and N are contracting such that they are forced towards each other to pump  
5 blood out of the ventricle. One measure of LV contraction effectiveness is called “contractility.” Left ventricular contractility is a measure of overall strength of the contracting power of the LV muscle cells. It is a function of the health of the LV muscle tissue and the coordination of the contractions of the entire LV, including walls M and N. Such coordination depends on the health of the left bundle branches  
10 and on the health of the fast conducting Purkinje fiber network. LV contractility is estimated by measuring the peak positive rate of change of the LV pressure during systole. In mathematical terms, this is the maximum positive derivative of the LV pressure, which is denoted by the term “LV  $+dp/dt$ ”.

LV systolic performance is also measured by stroke volume, which is  
15 the volume of blood pumped out of the LV per systole. Stroke volume can be estimated by measuring aortic pulse pressure (PP).

Cardiac muscle cells need to be electrically excited before they can have a mechanical contraction. During the excitation (depolarization), electrical signals will be generated and they can be recorded both intracardially and  
20 extracardially. The recorded signals are generally called electrocardiogram (ECG). An ECG recorded intracardially is also called an electrogram, which is recorded from an electrode placed endocardially or epicardially in an atrium or a ventricle. An ECG recorded extracardially is often called surface ECG, because it is usually recorded from two or more electrodes attached to the skin of the body. A complete  
25 surface ECG recording is from 12-lead configuration.

The features in ECG are labeled according to the origin of the electrical activity. The signals corresponding to intrinsic depolarization in an atrium and a ventricle are called P-wave and QRS complex, respectively. The QRS complex itself consists of a Q-wave, a R-wave, and a S-wave. The time interval  
30 from P-wave to R-wave is called PR interval. It is a measure of the delay between the electrical excitation in the atrium and in the ventricle.

Several disorders of the heart have been studied which prevent the heart from operating normally. One such disorder is from degeneration of the LV

conduction system, which blocks the propagation of electric signals through some or all of the fast conducting Purkinje fiber network. Portions of the LV that do not receive exciting signals through the fast conducting Purkinje fiber network can only be excited through muscle tissue conduction, which is slow and in sequential  
5 manner. As a result, the contraction of these portions of the LV occurs in stages, rather than synchronously. For example, if the wall N is affected by the conduction disorder, then it contracts later than the wall M which is activated through normal conduction. Such asynchronous contraction of the LV walls degrades the contractility (pumping power) of the LV and reduces the  $LV+dp/dt$  (maximum  
10 positive derivative of the LV pressure) as well.

Another disorder of the heart is when blood in the LV flows back into the LA, resulting in reduced stroke volume and cardiac output. This disorder is called mitral regurgitation and can be caused by an insufficiency of the mitral valve, a dilated heart chamber, or an abnormal relationship between LV pressure and LA  
15 pressure. The amount of the back flow is a complex function of the condition of the mitral valve, the pressure in the LV and in the LA, and the rate of blood flow through the left heart pump.

These disorders may be found separately or in combination in patients. For example, both disorders are found in patients exhibiting congestive  
20 heart failure (CHF). Congestive heart failure (CHF) is a disorder of the cardiovascular system. Generally, CHF refers to a cardiovascular condition in which abnormal circulatory congestion exists as a result of heart failure. Circulatory congestion is a state in which there is an increase in blood volume in the heart but a decrease in the stroke volume. Reduced cardiac output can be due to several  
25 disorders, including mitral regurgitation (a back flow of blood from the LV to the LA) and intrinsic ventricular conduction disorder (asynchronous contraction of the ventricular muscle cells), which are the two common abnormalities among CHF patients.

Patients having cardiac disorders may receive benefits from cardiac  
30 pacing. For example, a pacing system may offer a pacing which improves LV contractility, (positive LV pressure change during systole), or stroke volume (aortic pulse pressure), however, known systems require complicated measurements and fail to provide automatic optimization of these cardiac performance parameters.

Furthermore, the measurements are patient-specific and require substantial monitoring and calibration for operation. Therefore, there is a need in the art for a system which may be easily adapted for optimizing various cardiac parameters, including, but not limited to, LV contractility, (peak positive LV pressure change during systole,  $LV+dp/dt$ ), and cardiac stroke volume (pulse pressure). The system should be easy to program and operate using straightforward patient-specific measurements.

### Brief Description of the Drawings

FIG. 1 is a diagram of a heart showing the chambers and the nervous  
10 conduction system.

FIG. 2 is a diagram of a ventricle beginning contraction.

FIG. 3 is a diagram of a contracted ventricle.

FIG. 4A is a graph of left ventricle intrinsic pressure as a function of time as referenced to an intrinsic P-wave event.

15 FIG. 4B is a graph of left ventricle intrinsic electrogram as a function of time as referenced to an intrinsic P-wave event.

FIG. 4C is a timing diagram showing a marker of an intrinsic P-wave and the marker of a ventricular pacing pulse that is optimally timed for maximum LV contractility as referenced to a paced P-wave event;

20 FIG. 4D is a graph of left atrial intrinsic pressure as a function of time as referenced to an intrinsic P-wave event.

FIG. 4E is a timing diagram showing a marker of an intrinsic P-wave and the marker of a ventricular pacing pulse that is optimally timed for maximum stroke volume as referenced to a paced P-wave event.

25 FIG. 5A is a flow diagram for detection of a  $Q^*$  event.

FIG. 5B is one embodiment of an implantable medical device system implanted into a heart of a patient from which portions have been removed to show detail;

30 FIG. 5C is a block diagram of an implantable rhythm management device according to one embodiment of the present invention;

FIG. 5D is one embodiment of an implantable medical device system implanted into a heart of a patient from which portions have been removed to show detail;

FIG. 5E is one embodiment of an implantable medical device system implanted into a heart of a patient from which portions have been removed to show detail;

FIG. 5F is one embodiment of an electrocardiogram showing cardiac  
5 action currents of human subjects;

FIG. 6 is one embodiment of a schematic of an electrocardiogram showing cardiac action currents;

FIG. 7 is a flow diagram illustrating one embodiment of the present invention;

10 FIG. 8A, 8B, 8C and 8D are plots showing embodiments of correlations between sensed cardiac time intervals;

FIG. 9 is a plot showing an embodiment of optimal AV time delay intervals as a function of sensed cardiac time intervals;

FIG. 10 is a flow diagram illustrating one embodiment of the present  
15 invention;

FIGS. 11A and 11B are plots showing embodiments of optimal AV time delay intervals as a function of sensed cardiac time intervals; and

FIGS. 12A and 12B are plots showing embodiments of estimated optimal AV time delay intervals as a function of actual optimal AV time delay  
20 intervals.

FIG. 13 shows the selection between optimal hemodynamic cardiac parameters according to one embodiment of the present system.

### **Summary of the Invention**

This patent application describes multiple ways to provide optimized  
25 timing for ventricular pacing by determining certain intrinsic electrical or mechanical events in the atria or ventricles that have a predictable timing relationship to the delivery of optimally timed ventricular pacing that maximizes ventricular performance. This relationship allows prediction of an atrio-ventricular delay used in delivery of a ventricular pacing pulse relative to a sensed electrical P-  
30 wave of the atrium to establish the optimal pacing timing. Also provided are embodiments for measuring these events and deriving the timing relationship above. Those skilled in the art will understand upon reading the description that other events may be used without departing from the present invention.



In several embodiments, these measurements are used to optimize ventricular contractility as measured by maximum rate of pressure change during systole. In other embodiments, these measurements are used to optimize stroke volume as measured by aortic pulse pressure. In other embodiments, a compromise  
5 timing of pacing is available to provide nearly optimal improvements in both peak positive pressure change during systole and aortic pulse pressure. In one embodiment, this pacing is provided by adjusting the atrio-ventricular delay time interval, which is the time interval after a sensed P-wave, to deliver a pacing pulse to achieve the desired cardiac parameter optimization.

10 This summary of the invention is intended not to limit the claimed subject matter, and the scope of the invention is defined by attached claims and their equivalents.

#### Detailed Description

In the following detailed description, reference is made to the  
15 accompanying drawings which form a part hereof and in which is shown by way of illustration specific embodiments in which the invention can be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice and use the invention, and it is to be understood that other embodiments may be utilized and that electrical, logical, and structural changes may be made  
20 without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense and the scope of the present invention is defined by the appended claims and their equivalents.

Some of the embodiments illustrated herein are demonstrated in an implantable cardiac pacemaker, which may include numerous pacing modes known  
25 in the art. However, these embodiments are illustrative of some of the applications of the present system, and are not intended in an exhaustive or exclusive sense. For example, the present system is suitable for implementation in a variety of implantable and external devices.

The present system provides a means for optimizing cardiac systolic  
30 function based on different cardiac performance measurements. The present disclosure provides a number of embodiments useful for, among other things, optimizing cardiac pumping strength and stroke volume. The concepts described herein may be used in a variety of applications which will be readily appreciated by

those skilled in the art upon reading and understanding this description. The cardiac performance measurements expressly provided herein include contractility, peak positive ventricular pressure change, stroke volume, and pulse pressure. Other cardiac performance may be maximized using the teachings provided herein, and therefore, the express teachings of this disclosure are not intended in an exclusive or limiting sense. These concepts are expressly described in terms of the left ventricle, however, applications to other chambers of the heart, including the right ventricle, may be readily appreciated by those skilled in the art without departing from the present invention.

10           The patent application incorporates by reference the entire specification, including description, figures, appendices and any attachments filed in U.S. Provisional Patent Application Serial No. 60/084,704, filed May 8, 1998 and U.S. Patent Application Serial No. 09/075,278, filed May 8, 1998.

          The inventors of this subject matter performed numerous tests and experiments to develop a pacing system which may be used to treat cardiac disorders. The system includes method and apparatus which are useful for providing optimization of different cardiac performance parameters, including, but not limited to, ventricular contractility, maximum rate of pressure change during systole, stroke volume, and pulse pressure. The embodiments provided herein use right atrial (RA) sensing events to time the pacing of the left ventricle (LV), right ventricle (RV), or both (BV) to optimize cardiac performance parameters. However, it is understood that these teachings are applicable to other pacing configurations. The teachings herein provide, among other things, optimal pacing which is selectable for treating different cardiac disorders. The disorders include, but are not limited to, congestive heart failure (CHF), mitral regurgitation, and ventricular conduction disorder. The optimal pacing taught herein includes embodiments which do not use patient-specific measurements of hemodynamic parameters, such as pressure, blood flow, or measurements not typically provided by implantable pacing devices, and the system is capable of automatic adjustment to meet the needs of a particular patient.

30    **AVD Time Intervals**

          Implantable rhythm management devices such as pacemakers, are useful for treating patients with abnormal cardiac functions. One pacing therapy is called DDD pacing mode. In DDD pacing mode, pacing electrodes are placed in the

atrium (for example, the RA) and one or both of the ventricles. These electrodes are also used to sense electric signals from the atrium and the ventricle(s). If the device senses a signal in the atrium, it will inhibit the delivery of a pacing pulse to the atrium, otherwise it will pace the atrium after the end of a predetermined time period. Whenever the device senses or paces the atrium, it generates an event marker and at the same time starts an atrio-ventricular delay (AVD) time interval. At the end of this delay interval, the device will pace the ventricle(s) if no signals from the ventricle(s) are sensed by the device. Systems which provide ventricular pacing signals relative to the P-wave of an electrocardiogram signal refer to atrio-ventricular time delay interval (AVD time interval) as the time delay from the sensed P-wave to the delivery of the ventricular pacing signal. In patients exhibiting ventricular conduction disorder, such as the CHF condition, therapy using an AVD time interval which is shorter than the PR time interval may provide improved contractility because patients with degeneration of their LV conduction system require pacing of the affected parts of the LV (for example, the lateral wall N) early enough so that the contraction may be in phase with other parts of the LV that are excited by intrinsic conduction (for example wall M). Properly timed ventricular pacing can make both walls M and N contract in phase for increased contractility.

Patients with decreased stroke volume benefit from a shorter AVD time interval to decrease the mitral regurgitation effects and increase aortic pulse pressure. In addition, for congestive heart failure (CHF) patients, their PR interval may be prolonged which reduces the AV synchrony to some extent. Such a reduction in AV synchrony may further increase mitral regurgitation, and reduce the effect of preload of the LV. Use of a shorter AVD time interval increases pulse pressure by forcing the contraction of the LV into an earlier period, thus reducing the effects of mitral regurgitation.

#### **Optimization of Cardiac Ventricle Contractility and Maximum Left Ventricle Pressure Change during Systole**

Left ventricle contractility (pumping power) and peak positive rate of change of left ventricle pressure during systole (abbreviated as "LV+dp/dt") are related cardiac performance parameters. For instance, increases in LV contractility are observed in measurements as increases in left ventricle pressure change during systole.

FIG. 4A shows an intrinsic or unpaced left ventricle pressure curve following a P-wave. The Y event is the onset of intrinsic LV pressure increase. FIG. 4B shows an intrinsic left ventricular electrogram which is a QRS complex following a P-wave. Q\* is an electrical signal which occurs at the beginning of a QRS complex. R is the largest peak of the QRS complex. In FIG. 4B, the Q\* event leads the Y event of FIG. 4A. FIG. 4C shows a timing diagram under an optimally paced condition in which the LV contractility is maximized. The AVD<sub>c</sub> time interval is equal to the time between the P-wave marker and the ventricular pacing marker V and that pacing provides maximum LV contractility. It is therefore called an optimal atrio-ventricular delay for contractility. It is noted that in the FIG. 4C the P<sub>p</sub> marker is from a paced condition, as opposed to the P<sub>i</sub> markers in FIGS. 4A and 4B, which arise from intrinsic heart activity. Therefore P<sub>p</sub> occurs at a different time than P<sub>i</sub>. Additionally, the diagrams are not to scale.

In their experimentation, the inventors learned that when pacing for maximum contractility the Q\*, Y, and R events had a relatively predictable timing relationship with respect to the V pacing signal that is optimally timed by AVD<sub>c</sub>. Furthermore, the inventors learned that linear models could be created which map the PQ\* interval (the time difference between a P event and a Q\* event) to an optimal atrio-ventricular delay for maximum contractility, AVD<sub>c</sub>. Additionally, linear mappings are possible for PY and PR to AVD<sub>c</sub>, however, each mapping may result in different coefficients.

In one embodiment, an intrinsic PQ\* time interval is measured for a patient. This is the time interval between the P-wave and a Q\* event when no pacing signal is applied. After the PQ\* time interval is recorded and averaged, then a pacing signal is applied with varying atrio-ventricular delays while monitoring LV+dp/dt (peak positive left ventricular pressure change). Then the atrio-ventricular delay which produced the maximum LV+dp/dt (optimal contractility) is determined and named as AVD<sub>c</sub>, and is paired with that patient's PQ\* time interval. The PQ\*, AVD<sub>c</sub> pairs are generated for a number of other patients and the data are plotted. In one embodiment, a linear regression method is applied to determine a straight line approximation for AVD<sub>c</sub> as a function of PQ\*. The equation is:  $AVD_c = K1(PQ^*) - K2$ . A programmable device which measures the intrinsic PQ\* interval can estimate AVD<sub>c</sub> using this equation. Therefore, once K1 and K2 are determined, the

calibration of the device is complete. This means that subsequent patients may have optimal contractility pacing without requiring the pressure measurements and additional calibration stages. As described below, the same procedures may be used with PY or PR, however, as stated before, the coefficients may be different.

5                   This means that, if PQ\* is measured, then a patient may receive optimal contractility pacing of the left ventricle using measurements of the P-wave and of Q\*. In the case where PY is used instead of PQ\*, then the measurements will be of the P-wave and of the Y event, which is the onset of pressure increase in the left ventricular contraction. If the PR interval is used, then the measurements will be  
10 the P-wave and the R-wave of the QRS complex.

                  Therefore, given a patient's intrinsic PQ\* or PY or PR time interval and the respective mapping, an  $AVD_c$  is calculated. This  $AVD_c$  is an approximation of the actual  $AVD_c$  using the mapping method.

                  It is noted that any event which is relatively constant with respect to  
15 the optimally timed V pacing signal (pacing using  $AVD_c$ ) may be used as a predictable event for use in the present system. In one embodiment, an event which is relatively constant is one which has a deviation between the lesser of 20 ms or 25 percent of the population mean. Therefore, other embodiments incorporating events not expressly mentioned herein may be used without departing from the present  
20 system.

#### P-Wave Signal

                  When the electronic P-wave signal is used as a reference for any of the embodiments, the P-wave signal is detectable using devices including, but not limited to, catheters or external probes to create electrocardiograms. In one  
25 embodiment, the P-wave is sensed from the right atrium and used as a reference for the time interval measurements and pacing delivery. In some cases where a patient's atrium is paced then the P-wave pacing marker is used instead of the intrinsic P-wave.

#### PQ\* Measurement and Mapping

30                   As stated above, the inventors determined some "events" would have a predictable relationship to the optimally timed ventricular pacing signal. The Q\* event was defined as one candidate because it is relatively constant relative to the LV pacing mark, V, at optimal timing for maximum contractility. Q\* is an electrical

signal which occurs at the beginning of a QRS complex. Therefore, in one embodiment of the system, the time delay between the P-wave and the Q\* event is used to provide the linear variable to calculate  $AVD_c$ . In this embodiment, the equation is:  $AVD_c = K1 (PQ^*) - K2$ .

5 Furthermore, the inventors of the present system realized that the  $PQ^*$  interval provides a linear variable which may be used to estimate  $AVD_c$  using a single calibration procedure for determining the constants K1 and K2. One type of calibration was discussed above, mapping  $AVD_c$ ,  $PQ^*$  pairs in a linear fashion to provide K1 and K2. The  $PQ^*$  and  $AVD_c$  information is then plotted on a two-  
10 dimensional chart and a linear regression method is performed to provide a best line fit through the sample point pairs. This linear fit provides the K1 and K2 coefficients.

In one study using 13 patients, an equation for  $AVD_c$  was generated which provided K1 equal to 0.94 and K2 equal to 55.7 milliseconds. In this  
15 equation,  $PQ^*$  is measured in milliseconds. This equation is expressed as:  $AVD_c = 0.94 PQ^* - 55.7$  milliseconds. It is noted that the coefficients may vary and that estimated  $AVD_c$  may depart from the actual optimum  $AVD_c$  by approximately 20 percent and continue to provide near optimal performance within 80 percent of the maximum contractility. Furthermore, the coefficients may vary slightly depending  
20 on the number of samples taken in the calibration stage. Therefore, the coefficients provided herein may vary without departing from the present invention.

In one embodiment, the P-wave was detected using a threshold detector which indicated a P-wave at approximately 20 percent of the maximum P-wave amplitude in the right atrium. In one embodiment shown in FIG. 5A, the Q\*  
25 event is determined by passing the QRS complex as sampled from the left ventricle through a 5 point low-pass digital filter having a sampling time of 2 milliseconds, detecting the Q portion of the wave, calculating a maximum absolute value of the slope for the Q-wave, and indicating a point on the filtered Q-wave where the absolute value of the slope equals 2% of the absolute value slope of the Q-wave.  
30 Those skilled in the art will readily recognize that other determination methods may be used for P and Q\* which do not depart from the present system. Changes in the measurement techniques and slope criteria do not depart from the present system.

In another embodiment, the coefficient of  $PQ^*$ ,  $K1$ , is assumed to be unity, and the coefficient  $K2$  amounts to an offset time delay from the  $PQ^*$  interval to predict or estimate the optimal  $AVD_c$ . In this embodiment,  $PQ^*$  and  $AVD_c$  are sampled for a variety of patients at a variety of  $PQ^*$  intervals and a variety of  $AVD_c$  to generate a mean offset time delay  $K2$  for a number of patients. In this embodiment, the equation is as follows:  $AVD_c \text{ estimated} = PQ^* - Wa \text{ milliseconds}$ . Using the previous data for the 13 patients, the equation is:  $AVD_c \text{ estimated} = PQ^* - 67 \text{ milliseconds}$ . This embodiment provides an easier calculation, since a subtraction is less processor intensive than multiplications using floating point numbers. However, some accuracy is lost for the approximation.

It is noted that the coefficients may vary and that the estimated  $AVD_c$  may depart from the actual optimum  $AVD_c$  by approximately 20 percent and continue to provide near optimal performance within 80 percent of the maximum contractility. Furthermore, the coefficients may vary slightly depending on the number of samples taken in the calibration stage. Therefore, the coefficients provided herein may vary without departing from the present invention.

Those skilled in the art will readily recognize that other methods may be employed to generate other fits to the data which do not depart from the scope of the present invention.

In one embodiment, the measurements of the P-wave and  $Q^*$  are provided using an electrode implanted in the right atrium and an electrode implanted in the left ventricle. A programmable pulse generator is used to sense the P-wave and measure the time between occurrence of a sensed P-wave and a sensed  $Q^*$  event. The  $Q^*$  event is determined by electronics in the pulse generator which perform the required slope and comparison operations to determine  $Q^*$ . After a  $PQ^*$  time interval is determined, the  $AVD_c$  is determined using any of the embodiments described herein and their equivalents. Once the  $AVD_c$  is determined, it may be used in the next pacing interval to provide an optimized atrio-ventricular delay based on the  $PQ^*$  time interval.

It is understood that the  $Q^*$  event may be defined differently and provide substantially the same results with a different set of parameters,  $K1$  and  $K2$ . Furthermore, any electrical signal event which bears a predictable relationship to the beginning of intrinsic LV electrogram signals may be used in place of  $Q^*$ . For

example, in one embodiment the beginning of the RV electrogram may be used in place of Q\*. Or in another embodiment, the Q\* may be measured by surface ECG as the onset of the signal averaged QRS complex. Furthermore, information from more than one lead may be used to more accurately determine Q\*.

5 PR Measurement and Mapping

In another embodiment, the R-wave peak, which is the largest peak of the QRS complex of an intrinsic LV electrogram, is used since it has a predictable relationship to the delivery of optimally timed ventricular pacing for maximum contractility. In particular, the linear time relationship may be derived in terms of  
10 the PR interval for optimal atrio-ventricular delay for optimal left ventricular pressure change during systole. In this case, the equation is:  $AVD_c = N1 \text{ PR} - N2$ , where  $AVD_c$  is for pacing the LV, and PR is the time interval from right atrial sensing marker to the largest peak of the QRS complex of intrinsic LV electrogram. In one embodiment, the N1 and N2 coefficients are determined by mapping the PR  
15 time interval to the optimal  $AVD_c$  for a number of patients for optimal left ventricular pressure change during systole. In one study using 13 patients, the coefficient N1 is equal to 0.82 and the coefficient N2 is equal to 112 milliseconds. The equation for this calibration is:  $AVD_c = 0.82 \text{ PR} - 112$  milliseconds. It is noted that the coefficients may vary and that the estimated  $AVD_c$  may depart from the  
20 actual optimum  $AVD_c$  by approximately 20 percent and continue to provide near optimal performance within 80 percent of the maximum contractility. Furthermore, the coefficients may vary slightly depending on the number of samples taken in the calibration stage. Therefore, the coefficients provided herein may vary without departing from the present invention.

25 In another embodiment, the N1 coefficient is assumed to be unity, and the PR,  $AVD_c$  data pairs are averaged to provide a linear dependence with an offset equal to N2. This embodiment provides an easier calculation, since a subtraction is less processor intensive than multiplications using floating point numbers. However, some accuracy is lost for the approximation. For example,  
30 using data in the previous study:  $AVD_c = \text{PR} - 159$  milliseconds. In one embodiment, the R-wave signal is measured by detecting the largest peak of the QRS complex of the intrinsic LV electrogram. Therefore, electrical signals are used in this embodiment to provide the PR time interval, and therefore the optimal atrio-



ventricular delay for optimal left ventricular pressure change during systole. The coefficients N1 and N2 are provided in an initial calibration stage, which means that subsequent readings using this embodiment generate the optimal  $AVD_c$  automatically upon detection of the PR time interval. Furthermore, the N1 and N2 variables may change in value without departing from the teachings provided herein.

Other features of the QRS complex may be used for measurement. As stated above, these events may be used as long as they have a predictable timing relationship to the delivered pacing for optimal contractility. It is noted that the coefficients may vary and that the estimated  $AVD_c$  may depart from the actual optimum  $AVD_c$  by approximately 20 percent and continue to provide near optimal performance within 80 percent of the maximum contractility. Furthermore, the coefficients may vary slightly depending on the number of samples taken in the calibration stage. Therefore, the coefficients provided herein may vary without departing from the present invention.

#### 15 PY Measurements and Mappings

In another embodiment, a mechanical event is provided as a reference instead of an electrical event. In one embodiment, the mechanical event, Y is determined as the beginning of intrinsic LV pressure development. This means that a pressure transducer such as a micromonometer can provide instantaneous pressure data in the left ventricle. In this embodiment, the atrio-ventricular delay optimized for maximum left ventricular pressure change during systole is provided as:  $AVD_c = M1 PY - M2$ . In one embodiment, a micromonometer is placed in the LV to measure left ventricular pressure change during systole. The PY time interval, which is the time interval from right atrial sensing of the P-wave to the beginning of the intrinsic LV pressure development, is mapped to recorded  $AVD_c$  values for maximum left ventricular pressure change during systole. This mapping is plotted to perform a linear regression in order to determine the coefficients M1 and M2. In one study, M1 is equal to 0.96 and M2 is equal to 139 milliseconds. Therefore, in this study, the  $AVD_c = 0.96 PY - 139$  milliseconds. It is noted that the coefficients may vary and that the estimated  $AVD_c$  may depart from the actual optimum  $AVD_c$  by approximately 20 percent and continue to provide near optimal performance within 80 percent of the maximum contractility. Furthermore, the coefficients may vary slightly depending on the number of samples taken in the calibration stage.

Therefore, the coefficients provided herein may vary without departing from the present invention.

In another embodiment, the M1 coefficient is approximated as unity, and then the PY and  $AVD_c$  pairs are used to determine a linearized mapping which amounts to:  $AVD_c = PY - N_a$ , where  $N_a$  is an averaged offset delay for the samples taken. In one embodiment,  $AVD_c = PY - 150$  milliseconds. This embodiment provides an easier calculation, since a subtraction is less processor intensive than multiplications using floating point numbers. However, some accuracy is lost for the approximation. Again, it is noted that the coefficients may vary and that the estimated  $AVD_c$  may depart from the actual optimum  $AVD_c$  by approximately 20 percent and continue to provide near optimal performance within 80 percent of the maximum contractility. Furthermore, the coefficients may vary slightly depending on the number of samples taken in the calibration stage. Therefore, the coefficients provided herein may vary without departing from the present invention.

Other mechanical events may be used as long as they are relatively predictable with respect to the Y event. The Y events may be selected from signals including, but not limited to, ventricular pressure, cardiac phonogram, cardiac acoustic signals (such as recorded from an accelerometer external to or inside an implantable device), Doppler recording of atrio-ventricular valve motion, and M-mode, 2D, or 3D echo imaging of ventricular wall motion.

#### **Stroke Volume Optimization Using Atrio-Ventricular Delay**

Stroke volume is related to pulse pressure. The inventors discovered that for maximum pulse pressure (stroke volume), there is a predictable timing relationship between an optimally delivered ventricular pulse V and the peak of left atrial systole, X. Therefore, the optimal atrio-ventricular delay for maximum pulse pressure,  $AVD_s$ , is determined by PX time interval measurements, as shown in FIG. 4E.

In one embodiment, stroke volume is optimized by determining the atrio-ventricular delay for maximum aortic pulse pressure,  $AVD_s$ . In one embodiment, the X event is measured by placing a pressure sensing catheter inside the LA. In another embodiment, the X event is detected by measuring the LV pressure, because the LA contraction is seen in the LV pressure curve by a pre-systolic component. The peak of the LA systole is considered the same as the pre-

systolic pressure in the LV pressure curve. The time interval between P and the pre-systolic component of LV pressure provides a linear equation. Therefore, in order to generate the linear mapping of PX to  $AVD_s$ , a number of PX,  $AVD_s$  pairs are generated by measuring maximum aortic pulse pressure for varying PX. The linear relationship is expressed by:  $AVD_s = M3 PX - M4$  milliseconds. In one embodiment, a calibration procedure was performed to generate a number of PX,  $AVD_s$  pairs, which are mapped and a best line fit is performed to determine M3 and M4. In one embodiment, M1 is equal to 1.22 and M2 is equal to 132 milliseconds. Therefore, the  $AVD_s$  relationship is:  $AVD_s = 1.22 PX - 132$  milliseconds. It is noted that the coefficients may vary and that the estimated  $AVD_s$  may depart from the actual optimum  $AVD_s$  by approximately 20 percent and continue to provide near optimal performance of the maximum stroke volume. Furthermore, the coefficients may vary slightly depending on the number of samples taken in the calibration stage. Therefore, the coefficients provided herein may vary without departing from the present invention.

In one embodiment, the P-wave event is measured using a threshold detection where the P-wave is determined to be 20 % of the maximum P-wave amplitude. Other detection methods for the P-wave may be used without departing from the present system. The X event may be determined by several ways, including but not limited to: locating the point of maximum atrial pressure, Doppler measurements, and S4 components of accelerator measurements.

Other embodiments using different values for M3 and M4 are possible without departing from the present system. Furthermore, other markers may be used which are directly related to the PX time interval provided in one embodiment.

It is noted that any event which is relatively constant with respect to the optimally timed V pacing signal (pacing using  $AVD_s$ ) may be used as a predictable event for use in the present system. In one embodiment, an event which is relatively constant is one which has a deviation between the lesser of 20 ms or 25 percent of the population mean. Therefore, other embodiments incorporating events not expressly mentioned herein may be used without departing from the present system.

### **Selection of Atrio-Ventricular Delay for Improved Contractility and Stroke Volume**

Depending on the condition of a heart and its disorders, optimal atrio-ventricular delay for maximum contractility may provide especially nonoptimal stroke volume. Likewise, optimal atrio-ventricular delay for maximized stroke volume may result in nonoptimal contractility. Therefore, in order to provide a compromised atrio-ventricular delay which provides an approximately optimal atrio-ventricular delay for both contractility and stroke volume,  $AVD_{cs}$ , it is desirable to have an atrio-ventricular delay which provides near optimal contractility and near optimal stroke volume. The inventors of the present system derived a relationship which provides a compromise between optimal contractility and optimal stroke volume. In one embodiment, the optimized atrio-ventricular delay,  $AVD_{cs}$ , is a linear relationship in the PR time interval, as follows:  $AVD_{cs} = K3 PR_m - K4$  milliseconds.  $PR_m$  is a time interval measured from a right atrial sensing marker, P, to a right ventricular sensing marker,  $R_m$ . In one embodiment, the compromised  $AVD_{cs}$  is provided by determining  $AVD_c$  and  $AVD_s$  for a number of PR values and for a number of patients. Then a linear regression provides a best line fit for both contractility and stroke volume. In one embodiment,  $AVD_{cs}$  equals  $0.5 PR_m - 15$  milliseconds, where  $AVD_{cs}$  is for pacing at least one ventricle, and where the time interval  $PR_m$  is measured from a right atrial sensing marker, P, to a right ventricular sensing marker,  $R_m$ . In this embodiment, the resulting atrio-ventricular delay provides a left ventricular pressure change within 90% of the optimal left ventricular pressure change during systole. Furthermore, this embodiment provides an aortic pulse pressure which is within 80% of the optimal aortic pulse pressure. It is noted that the coefficients may vary and still provide a reasonable approximation of  $AVD_{cs}$ . For example, in one embodiment K3 may be in the range from 0.4 to 0.6 and K2 may be in the range from 0 to 30 ms. Therefore, the present system offers flexibility in the selection of coefficients, and those provided are demonstrative and not an exclusive set of coefficients.

In one embodiment, a left ventricular event is used to provide a time interval for calculation of  $AVD_{cs}$ . In one case the LV event is the LV R-wave. The LV R-wave marker signal may also be used as an event. It is noted that any event which is relatively constant with respect to the near optimally timed V pacing signal

may be used as a predictable event for use in the present system. In one embodiment, an event which is relatively constant is one which has a deviation between the lesser of 20 ms or 25 percent of the population mean. Therefore, other embodiments incorporating events not expressly mentioned herein may be used  
5 without departing from the present system.

In one embodiment, the left ventricular R wave is used to develop a relationship between the PR interval (the time interval between a P event and an R event) and  $AVD_{cs}$ . For a particular patient, the intrinsic PR interval is measured. Additionally, a sweep of atrio-ventricular delays are applied to the pacing of the  
10 patient and  $LV+dp/dt$  and pulse pressure are measured for each different atrio-ventricular delay. The  $LV+dp/dt$  data is plotted against a normalized value of the atrio-ventricular delay. Additionally, the pulse pressure is also plotted against a normalized value of the atrio-ventricular delay. In one embodiment, the atrio-ventricular delay is divided by  $PR-30$  ms to normalize the delay. The tests are  
15 performed for a number of additional patients and the normalized plots are mapped. Then an averaging of the various  $LV+dp/dt$  vs. normalized atrio-ventricular delay data is performed. An averaging of the pulse pressure data vs. normalized atrio-ventricular delay data is also performed. The atrio-ventricular delay (normalized value) at the  $LV+dp/dt$  curve peak is used as an optimal averaged atrio-ventricular  
20 delay. The peak of the pulse pressure curve is also determined. In one example, the optimal averaged normalized atrio-ventricular delays for both curves was determined to be approximately 0.50 times the normalized PR time interval, or  $0.50(PR-30)$  milliseconds.

In one study data was taken using a series of intermittent pacing (5  
25 pacing beats in every 15 sinus beats) from one of three sites (RV, LV, and BV) at one of five AV delays (equally spaced between 0 msec and  $PR-30$  msec). Each pacing site/AV delay combination was repeated five times in random order. Pressure and electrogram data were recorded from the ventricles.  $LV+dp/dt$  and PP were measured from LV and aortic pressure recordings on a beat-by-beat basis. For  
30 each paced beat, values of the  $LV+dp/dt$  and PP were compared to a preceding 6-beats-averaged sinus baseline. Then the response to pacing configuration was averaged. However, other measurements may be taken to obtain the required information.

### Switchable Pacing Therapies

Any of the teachings provided herein may be employed in a variety of cardiac devices, including implantable pacing devices, such as shown in FIGS 5B-5E. In one embodiment, an implantable device also includes means for changing the ventricular pacing to adjust for maximum contractility, maximum stroke volume or a compromise providing nearly optimal contractility and stroke volume. In such an embodiment, the pacing system contemplates the use of all of the different optimal atrio-ventricular delays to adjust the therapy to a cardiac patient. In one embodiment  $AVD_{cs}$  is used as a default atrio-ventricular pacing delay, which may be maintained or modified at a later time depending on the therapy required. For example, in one embodiment of the system, the pacing initiates with an atrio-ventricular delay equal to  $AVD_{cs}$ . If at any time an optimal contractility is required, the atrio-ventricular pace delay is changed to  $AVD_c$ . Additionally, if at any time optimal stroke volume is required, the atrio-ventricular delay is changed to  $AVD_s$ . Other variations and combinations are possible without departing from the present invention. Furthermore, the switching of the pacing therapies may be provided by an external instruction, such as a programmer, or by an internally executing software for selecting the appropriate therapy. Other ways of switching between therapies may be encountered which do not depart from the present system.

### Experimental Findings

Detailed experimental findings are attached as an Appendix in U.S. Provisional Patent Application Serial No. 60/084,704 following the Abstract. Referring now to FIG. 5F, there is shown electrocardiogram traces of left ventricular QRS complexes 200 from patients having congestive heart failure (CHF). The QRS complexes 200 were recorded epicardially from the free wall regions of the patient's left ventricle. FIG. 5F shows the QRS complexes 200 having the peaks, or maximum deflection points, of the R points 202 aligned. The data shows a uniform pattern in electrical depolarization in the left ventricle of CHF patients, as the QRS complexes 200 have very similar durations. Sensed P-waves 204 from each patient are also displayed. As the data indicates, aligning the maximum deflection points of the R points 202 shows that the time interval between the atrial sensing or pacing marks of the P-waves 204 and the start 206 of the QRS complexes 200 varies from patient to patient. Because the R points 202 have been aligned, this necessarily

means that the PR interval, the time interval between the atrial sensing or pacing mark of a sensed P-wave 204 and the maximum deflection point of a sensed R point 202, also varies from patient to patient.

Referring now to FIG. 6, there is shown a schematic drawing of an electrocardiogram 300. The electrocardiogram 300 includes indications of cardiac events that occur during the normal cardiac cycle. The indications are shown in FIG. 6, where 302 represents the atrial sensing or pacing mark of a P-wave; 304 represents a Q\* point, the beginning of the QRS complex; 306 represents the occurrence of a Q point, the maximum point before the beginning of the R point; 308 represents the occurrence of the R point, the maximum deflection point of the QRS complex in sinus rhythm; 310 represents the occurrence of the S point, the maximum point after the R point; and 312 represents an S\* point, the end of the QRS complex. In one embodiment, these cardiac events displayed in electrocardiogram 300 are detected through the use of an implantable rhythm management device.

The electrocardiogram 300 also shows representations of a variety of time intervals between the cardiac events. A PQ\*-time interval 314 is the time interval between a sensed P-wave 302 and Q' point 304. A PQ-time interval 316 is the time interval between a sensed P-wave 302 and a sensed Q point 306. A PR-time interval 318 is the time interval between a sensed P-wave 302 and a sensed R point 308. A PS-time interval 320 is the time interval between a sensed P-wave 302 and a sensed S point 310. A PS'-time interval 322 is the time interval between a sensed P-wave 302 and S' point 312. In one embodiment, the microprocessor 58 receives the sensed P-wave and QRS complex and determines the time intervals between the wave portions of the cardiac cycle. In an alternative embodiment, surface ECG measurements are made, through the use of a 2-point lead surface ECG, from which the time intervals between the wave portions of the cardiac cycle are determined.

Referring now to FIG. 7, there is shown a flow chart of one embodiment of the present invention for determining a model of the heart. In one embodiment, the model of the heart is used to determine an estimated optimal AV time delay interval. At step 350, a plurality of patients are tested, where each of the patient's have cardiac pacing pulses delivered to a ventricular chamber of the

patient's heart. The cardiac pacing pulses are delivered at a plurality of predetermined AV time delay intervals. In one embodiment, the AV time delay intervals are measured from the occurrence of the patient's P-wave. For each patient, LV+dp/dt values are measured and recorded for each of the plurality of AV time delay intervals tested. In an alternative embodiment, the aortic pulse pressure is measured and recorded for each of the plurality of AV time delay intervals tested. In one embodiment, the data was acquired from patients who were paced at the left ventricular free wall with 5 different AV delay time intervals, where the AV delay time intervals were delivered in a randomized order.

10 In one embodiment, this type of testing is performed on patients who exhibit a common cardiac condition. For example, in the present embodiment the patients tested were all CHF patients. In addition, the cardiac pacing pulses used in determining the model can be delivered to any number of locations in the ventricular region of the heart. In one embodiment, the cardiac pacing pulses are delivered to an epicardial location on the patient's left ventricular chamber, such as at the left ventricular free wall as previously mentioned. In an alternative embodiment, the cardiac pacing pulses are delivered to an endocardial location that is adjacent to the patient's left ventricular chamber. In an additional embodiment, the cardiac pacing pulses are delivered to an endocardial location in the patient's right ventricular chamber. Additionally, different combinations of right ventricular and left ventricular pacing can be used in determining, or testing for, the maximum left ventricular systolic performance.

In addition to providing cardiac pacing pulses at a number of locations in the ventricular region of the heart, intrinsic electrocardiograms signals are also recorded during the testing of the predetermined AV time delay intervals. In one embodiment, the intrinsic electrocardiogram signals are recorded epicardially from the left ventricular free wall. In one embodiment, the intrinsic electrocardiograms are measured and recorded through the use of a standard 12-point lead surface ECG measurement. The electrocardiograms were digitized (sampling frequency: 500 Hz; resolution: 14 bit) and analyzed offline using specially designed software.

At step 360, the times for the AV time delay interval and the corresponding left ventricular systolic performance measurements from each of the



patients are analyzed. Each patient's data is analyzed to determine the AV time delay interval that produced the maximum left ventricular systolic performance. For each patient, the predetermined AV time delay interval producing the maximum left ventricular systolic performance is recorded and stored for use in determining the  
5 model of the heart. Along with determining the AV time delay that produces the maximum left ventricular systolic performance, time differences between predetermined features on the electrocardiogram signals recorded during the test are also determined. In one embodiment, the electrocardiogram signals recorded during the test are used to determine a feature time difference at step 360.

10 In one embodiment, the feature time difference is determined between a first predetermined feature on a sensed P-wave and a second predetermined feature on a sensed QRS-complex from the patient's heart that has been paced at the predetermined AV time delay interval that produced a maximum left ventricular systolic performance. In one embodiment, the feature time  
15 difference is derived from the atrial sensing or pacing mark of the sensed P-wave and the beginning portion of the sensed QRS-complex (Q\* point) from a left ventricular electrocardiogram signal. This value is the PQ\*-time interval 314 as previously described. In an alternative embodiment, the feature time difference is derived from an atrial sensing or pacing mark of the sensed P-wave and a maximum  
20 deflection point of an R point of the sensed QRS-complex from a left ventricular electrocardiogram signal. This value is the PR-time interval 318 as previously described. In an additional embodiment, the PR-interval feature time difference is derived from a right ventricular electrocardiogram signal. Measured PQ'-time  
25 interval 314 and PR-time interval 318 values from normal QRS complexes were averaged and then used to derive the model for determining the estimated optimal AV time delay intervals. In addition, other feature time differences exist which could be used in determining a model of the heart from determining estimated optimal AV time delay interval values.

For the CHF patients, time values for Q' points 304, Q points 306, R  
30 points 308, S points 310, and S' points 312 from the QRS complexes were determined and the PQ'-time interval 314, PQ-time interval 316, PR-time interval 318, PS-time interval 320, and PS'-time interval 322 were calculated. An average for each of the PQ'-time interval 314, PQ-time interval 316, PR-time interval 318,

PS-time interval 320, and PS'-time interval 322 was then calculated along with their respective standard deviation. Values of a measured time interval that were at least one standard deviation away from the mean were removed and the remaining time interval data points were averaged again to obtain final mean for the PQ'-time  
5 interval 314, PQ-time interval 316, PR-time interval 318, PS-time interval 320, and PS'-time interval 322.

At step 370, a model of the heart is generated from the feature time difference and the predetermined AV time delay interval that produced the maximum left ventricular systolic performance. In one embodiment, the model is  
10 generated from the relationship of the feature time differences and the predetermined AV time delay intervals for the patients. One way of determining this relationship is to map the patients predetermined AV time delay interval data versus the corresponding feature time difference on a Cartesian coordinate system. Based on the mapped data, a model of the heart is derived that is subsequently used in  
15 determining an estimated optimal AV time delay interval. In one embodiment, the model of the heart for determining an estimated optimal AV time delay interval is a linear model. In one embodiment, the model is used in an electrical pulse generating device to provide therapy to the heart, such as providing pacing pulses to CHF patient's to improve their cardiac output efficiency.

20 Referring now to FIG.s 8A, 8B, 8C and 8D there is shown plots demonstrating correlations between pairs of the PQ'-time interval 314, PQ-time interval 316, PR-time interval 318, PS-time interval 320, and PS'-time interval 322 for the CHF patients. Data collected from CHF patients indicates there is a high correlation between PQ'-time interval 314 and PQ-time interval 316 (FIG. 8A); PR-  
25 time interval 318 and PQ-time interval 316 (FIG. 8B); and PS-time interval 322 and PR-time interval 318 (FIG. 8C). These correlations indicate that the time intervals from the Q' points 304 to the Q points 306; from the Q points 306 to the R points 308; and from the R points 308 to the S points 310 are nearly independent of the PQ'-time interval 314, PQ-time interval 316, PR-time interval 318, PS-time interval  
30 320, and PS'-time interval 322. In other words, the location of P-wave 302 has a limited effect on the inter-difference between the Q' points 304, the Q points 306, the R points 308, and the S points 310.

The data from FIG.s 5F and 8 indicates that the electrical activation pattern of the left ventricular is highly similar for the tested patients. Once the cardiac signal has traveled into the Purkinje's network and into ventricles, which coincide with the beginning of the QRS complex and the stimulation of the

5 ventricles, the remainder of the cardiac cycle was similar for the patients under the study. Based on these observations, specific electrical activation patterns required to achieve optimal LV synchrony have been found to be similar among the patients. The time interval between the beginning of the electrical activation in the LV (as indicated by Q') and the pacing mark may be similar among the patients at their

10 optimal AV time delay interval for LV synchrony. As a result, differences in optimal AV time delay intervals for LV synchrony may be largely due to the differences from the P-wave to the beginning of the electrical activation of the left ventricle (i.e., PQ').

Referring now to FIG. 9 there is shown a Cartesian coordinate system

15 for mapping predetermined AV time delay interval values against feature time differences. Actual data points 400 collected for each of the patients are mapped on the coordinate system. Based on the actual data points 400 mapped on the coordinate system, a model representing the data points 400 is generated. In one embodiment, the model generated is a linear model which is determined from a

20 performing a linear regression on the actual data points 400. The linear model is used to generate a trend line 410 on the coordinate system. In one embodiment, the trend line 410 represents a best overall relationship between the actual optimal AV time delay interval values and the values of the feature time differences. In one embodiment, modeling the data through linear regression allows the mean square

25 differences, 420, between the actual and estimated AV delays to be minimized. The better the correlation between actual data and the model representing the data points, the better the trend line 410 will represent the relationship between the data.

Referring to FIG. 10, there is shown a flow diagram of one embodiment of the present invention. The cardiac signal circuitry housed within the

30 implantable cardiac pacemaker 22 senses the occurrence of the patient's electrocardiogram signals. At step 500, the microprocessor determines a time interval from features on the sensed electrocardiogram signals. In one embodiment, the microprocessor determines the time interval from sensed P-waves and QRS-

complexes. At step 510, the microprocessor uses the time interval in a model, such a linear model to generate an estimated optimal AV time delay interval. Then at step 520, the pacing output circuitry of the implantable cardiac pacemaker 22 is used to generate a pacing pulse based on the estimated optimal AV time delay interval to enhance a left ventricular contractility (LV+dp/dt).

Referring now to FIG.s 11A and 11B there is shown mappings of the relationship between the feature time differences in the electrocardiogram signals and the predetermined AV time delay intervals that produced the maximum left ventricular systolic performances (LV dp/dt) for the tested patients. From these mappings, models are generated that express the relationship of the feature timing differences to estimated optimal AV time delay intervals. In one embodiment, the models based on FIG.s 11A and 11B represent the best overall relationship between the actual optimal AV time delay interval and the values of the PQ'-time interval 314 and the PR-time interval 318, respectively.

In one embodiment, FIG. 11A shows a mapping of the correlation between the PQ'-time interval 314 and the predetermined AV time delay interval that produced the maximum left ventricular systolic performance. Line 600 on FIG. 11A was derived by linear regression based on the plotted data points. Since the line 600 is linear, the estimated optimal AV time delay interval for LV dp/dt can be written as a linear function of the PQ'-time interval 314 where:

$$AVD_{opt-\frac{dp}{dt}} = k1 \cdot PQ' - k2 \quad (1)$$

Where AVD is an estimated optimal AV time delay interval,  $k1$  is a first coefficient,  $k2$  is a second coefficient, and PQ\* is a time interval derived from features on an electrocardiogram signal. In one embodiment, PQ\* is the PQ\*-time interval 314. Additionally, the first coefficient and the second coefficient are empirically derived from the mapping of the time interval (in this instance the PQ\*-time interval) and an optimal AV time delay interval.

In one embodiment, equation (1) is utilized within the electronic control circuitry 50 of the implantable cardiac pacemaker 22 to determine an estimated optimal AV time delay interval from the patient's sensed

electrocardiogram signals. In one embodiment, equation (1) is used to determine an optimal AV time delay interval based on the patient's electrocardiogram sensed from an atrial and a left ventricular location. In one embodiment, the cardiac signal circuitry housed within the implantable cardiac pacemaker 22 senses the occurrence of both the patient's P-wave and the Q\*point during a cardiac cycle. The microprocessor 58 receives the sensed P-wave and Q\* point and determines a time interval between these two features. The time interval is then used in equation (1) to generate the AV time delay interval. The implantable cardiac pacemaker 22 then provides pacing pulses to at least one ventricle of the patient's heart at the calculated AV time delay interval to enhance the left ventricular peak ejection pressure. In one embodiment, pacing at the left ventricular location is accomplished through the use of the ventricular catheter, 26 or 152. In an additional embodiment, the pacing pulses generated by the implantable cardiac pacemaker based on equation (1) are generated in real time from the patient's sensed electrocardiogram signals.

In one embodiment, when equation (1) is used to determine the estimated optimal AV time delay interval and the pacing pulses are delivered to a left ventricular location, the first coefficient,  $k_1$ , has a value that is approximately equal to 0.93 and the second coefficient,  $k_2$ , has a value that is approximately equal to 55.8. It is intended that these coefficient values are not limited to the values shown, and any coefficient values derived from the relationship between actual optimal AV time delay intervals and features on electrocardiogram signals are considered to be within the scope of the present invention.

In an additional embodiment, FIG. 11B shows a mapping of the correlation between the PR-time interval 318 and the predetermined AV time delay interval that produced the maximum left ventricular systolic performance. Line 610 on FIG. 11B was derived by linear regression based on the plotted data points. Since the line 610 is linear, the estimated optimal AV time delay interval for LV dp/dt can be written as a linear function of the PR-time interval 318 where:

$$AVD_{opt} - \frac{dp}{dt} = k_1 \cdot PR - k_2 \quad (2)$$

Where AVD is an estimated optimal AV time delay interval,  $k_1$  is the first coefficient,  $k_2$  is the second coefficient, and PR is a time interval derived from features on an electrocardiogram signal. In one embodiment, PR is the PR-time interval 318. Additionally, the first coefficient and the second coefficient are  
5 empirically derived from the mapping of the time interval (in this instance the PR-time interval) and an optimal AV time delay interval.

In one embodiment, equation (2) is utilized within the electronic control circuitry 50 of the implantable cardiac pacemaker 22 to determine an estimated optimal AV time delay interval from the patient's sensed  
10 electrocardiogram signals. In one embodiment, equation (2) is used to determine an optimal AV time delay interval based on the patient's electrocardiogram sensed from an atrial and a left ventricular location. The estimated optimal AV delay interval from equation (2) is then used to time the delivery of a pacing pulse to the patient's left ventricle. In one embodiment, pacing at the left ventricular location is  
15 accomplished through the use of the ventricular catheter, 26 or 152. In an additional embodiment, the pacing pulses generated by the implantable cardiac pacemaker based on equation (2) are generated in real time from the patient's sensed electrocardiogram signals.

In one embodiment, when equation (2) is used to determine the  
20 estimated optimal AV time delay interval and the pacing pulses are delivered to a left ventricular location, the first coefficient,  $k_1$ , has a value that is approximately equal to 0.82 and the second coefficient,  $k_2$ , has a value that is approximately equal to 112.4. It is intended that these coefficient values are not limited to the values shown, and any coefficient values derived from the relationship between actual  
25 optimal AV time delay intervals and features on electrocardiogram signals are considered to be within the scope of the present invention.

Referring now to FIG.s 12A and 12B, there are shown plots of estimated optimal AV time delay intervals as a function of actual optimal AV time delay intervals. The estimated optimal AV time delay interval values were  
30 calculated using equation (1) and (2), where the feature time differences were determined from the patient's sensed atrial and left ventricular electrocardiograms. Table 1 shows the differences between the estimated optimal AV time delay interval

determined using equation (1) and the actual optimal AV time delay interval using the PQ\*-time interval 314 for CHF patients.

5 Differences Between Estimated and Actual Optimal AV time delay interval

Patient	Actual Optimal AV time delay interval (for dp/dt) (ms)	Estimated Optimal AV time delay interval Using PQ', $k1 = 0.93, k2 = 55.8$	Relative Difference (%) (= 100   (actual-estimated)/ actual   )
2	78	71	9
3	45	50	12
5	150	134	11
10 6	95	98	3
7	158	162	3
8	75	28	4
9	110	85	23
10	100	96	4
15 11	125	133	6
12	55	63	14
15	55	53	3
16	95	100	6
18	85	95	12

20 Mean = 8%, STD = 6%

**Table 1**

Table 2 shows the differences between the estimated optimal AV time delay interval determined using equation (2) and the actual optimal AV time delay interval using the PR-time interval 318 for CHF patients.

25

Differences Between Estimated and Actual Optimal AV time delay interval

Patient	Actual Optimal AV time delay interval (for dp/dt) (ms)	Estimated Optimal AV time delay interval Using PR, $k_1$ $= 0.82$ , $k_2 = 112.4$	Relative Difference (%) ( $= 100   (\text{actual}-\text{estimated}) / \text{actual}  $ )
2	78	83	6
3	45	64	42
5	150	123	18
6	95	107	13
7	158	166	5
8	75	81	8
9	110	103	6
10	100	104	4
11	125	124	0.4
12	55	46	16
15	55	49	10
16	95	85	10
18	85	100	18

Mean = 12%, STD = 11%

**Table 2**

In one embodiment, the first coefficient and the second coefficient for equation (1) and equation (2) are determined from line 430 and line 440, respectively, and are, therefore, dependent upon the data points on which the line is drawn. The sensitivity of the coefficients was tested with respect to a change in the size of the data group. Different numbers of data points (i.e., number of patients) were used to generate line 430 in a plot of actual optimal AV time delay interval versus the PQ'-time interval 314, and to generate line 440 in a plot of actual optimal AV time delay interval versus the PR-time interval 318. Values for the first coefficient,  $k_1$ , and the second coefficient,  $k_2$ , were obtained from the line 430 equation in the plot for PQ' and from the line 440 equation in the plot for PR.



Equation (1)					Equation (2)				
	No. of data points	$k1$	$k2$	$r^2$		No. of data points	$k1$	$k2$	$r^2$
5	2	1.47	123.1	1		2	1.44	265.8	1
	3	1.14	82.2	0.99		3	1.46	268.8	1
	4	1.12	81.0	0.97		4	1.32	240.1	0.92
	5	0.965	59.7	0.90		5	0.946	149.7	0.88
	6	0.974	61.9	0.96		6	0.942	148.4	0.89
10	7	0.943	53.3	0.91		7	0.941	146.6	0.88
	8	0.943	53.4	0.92		8	0.941	146.8	0.88
	9	0.904	48.3	0.91		9	0.941	146.9	0.88
	10	0.938	55.1	0.91		10	0.854	122.3	0.88
	11	0.937	55.0	0.92		11	0.828	114.9	0.89
15	12	0.934	55.1	0.92		12	0.822	112.4	0.89
	13	0.933	55.8	0.91		13	0.817	112.4	0.87
	14	0.943	57.7	0.92		14	0.841	120.3	0.85

After five data points, the  $k1$  and  $k2$  values for equation (1) did not change significantly. The value of  $k1$  oscillates between 0.904 and 0.974, and  $k2$  oscillates between 48.3 and 61.9. On the other hand, the  $k1$  and  $k2$  values for equation (2) experienced a continuous delay as the number of data points increased. As a result, the  $k1$  and  $k2$  values used in equation (1) are less sensitive to the number of data points than the  $k1$  and  $k2$  values used in equation (2). So, in one embodiment, the PQ'-time interval 314, as used in equation (1), is more accurate and robust to predict an optimal AV time delay interval than using the PR-time interval 318 in equation (2). In addition, observing the mean difference between the actual and estimated optimal AV time delay interval of Tables 1 and 2, using the PQ'-time interval 314 provides a more accurate result than using the PR-time interval 318. However, the PR-time interval 318 is more easily measured using an implantable medical system 20, such as the implantable cardiac pacemaker 22 previously described or an implantable defibrillator, than the PQ'-time interval 314.

In an additional embodiment, equation (2) is also used to determine estimated optimal AV time delay intervals when electrocardiogram signals are sensed from an atrial and at least a right ventricle location. Based on a mapping of the relationship between the PR-time interval feature time difference in the right ventricular electrocardiogram signals and the predetermined AV time delay intervals

that produced the maximum left ventricular systolic performances (LV dp/dt) for the tested patients, a linear model having the form of equation (2) was generated. The line representing the linear model was derived by linear regression based on the plotted data points.

5                   In one embodiment, equation (2) is utilized within the electronic control circuitry 50 of the implantable cardiac pacemaker 22 to determine an estimated optimal AV time delay interval from the patient's sensed electrocardiogram signals. In one embodiment, equation (2) is used to determine an optimal AV time delay interval based on the patient's electrocardiogram sensed from  
10 an atrial and at least a right ventricular location. The estimated optimal AV delay interval from equation (2) is then used to time the delivery of a pacing pulse to the patient's right ventricle. In one embodiment, pacing at the right ventricular location is accomplished through the use of the ventricular catheter, 100 or 150. In an additional embodiment, the pacing pulses generated by the implantable cardiac  
15 pacemaker based on equation (2) are generated in real time from the patient's sensed electrocardiogram signals.

                  In an alternative embodiment, the optimal AV delay interval determined using equation (2) is used to time the pacing of the heart from a left ventricular location. In an additional embodiment, the optimal AV delay interval  
20 determined using equation (2) is used to time the pacing of the heart from both a right ventricular and a left ventricular location. In one embodiment, the medical device system 20, as previously described, is used to provide pacing pulses to at least one of a right ventricle and a left ventricle of the heart.

                  In one embodiment, when equation (2) is used to determine the  
25 estimated optimal AV time delay interval and the pacing pulses are delivered to at least a right ventricular and a left ventricular location, the first coefficient,  $k_1$ , has a value that is approximately equal to 0.5 and the second coefficient,  $k_2$ , has a value that is approximately equal to 30.0. It is intended that these coefficient values are not limited to the values shown, and any coefficient values derived from the  
30 relationship between actual optimal AV time delay intervals and features on electrocardiogram signals are considered to be within the scope of the present invention.

**Conclusion**

The present pacing system may be employed in a variety of pacing devices, including implantable pacing devices. The present system may be used for pacing one or more ventricles. A variety of pacing electrode configurations may be employed without departing from the present invention including multiple pacing sites at a ventricle(s), provided that the required electrical or mechanical events are monitored. Changes in the coefficients and order of methods provided herein may be practiced accordingly without departing from the scope of the present invention.

**What is claimed is:**

1. An apparatus, comprising:  
a programmable pulse generator transmitting ventricular pacing pulses with an atrio-ventricular delay ( $AVD_c$ ) produced from an interval between a first  
5 electrical event and a second electrical event, the first electrical event related to an atrial contraction in a first predictable time-dependent relationship and the second electrical event related to a ventricular pacing signal that is optimally timed for maximum  $LV+dp/dt$  in a second predictable time-dependent relationship, the interval measured during a nonpaced systolic cycle;  
10 wherein the  $AVD_c$  is produced from a predetermined mapping of the relationship of the interval to an optimal atrio-ventricular delay for maximum  $LV+dp/dt$  and  
wherein  $AVD_c$  provides an approximation of the optimal atrio-ventricular delay for pacing the ventricle to provide maximum  $LV+dp/dt$ .  
15
2. The apparatus according to claim 1, wherein the first electrical event is a P-wave, the second electrical event is a beginning of a QRS complex ( $Q^*$ ), and the interval is between the P-wave and  $Q^*$  ( $PQ^*$ ).
- 20 3. The apparatus according to claim 2, wherein  $AVD_c$  is calculated from a linear equation:  $AVD_c = K1 (PQ^*) - K2$ .
4. The apparatus according to claim 3, wherein  $K1$  is approximately 0.94 and  $K2$  is approximately 55.7 milliseconds.
- 25 5. The apparatus according to claim 3, wherein  $K1$  is approximately 1.0 and  $K2$  is approximately 67 milliseconds.
6. The apparatus according to claim 3, wherein  $PQ^*$  is measured using a  
30 programmable pulse generator having an electrode in a right atrium and an electrode sensing signals from a left ventricle.

7. The apparatus according to claim 6, wherein the P-wave is detected when it reaches 20 percent of a maximum P-wave amplitude in the right atrium.
8. The apparatus according to claim 6, comprising a low pass filter for detecting  
5 Q\*.
9. The apparatus according to claim 8, wherein Q\* is detected when a slope of a Q-wave reaches 2 percent of its maximum absolute value of the Q-wave slope.
- 10 10. The apparatus according to claim 3, wherein PQ\* is measured using surface EKG.
11. The apparatus according to claim 1, wherein the first electrical event is a P-wave, the second electrical event is a peak of an R-wave (R), and the interval is  
15 between the P-wave and R (PR).
12. The apparatus according to claim 11, wherein  $AVD_c$  is calculated from a linear equation:  $AVD_c = N1 (PR) - N2$ .
- 20 13. The apparatus according to claim 12, wherein N1 is approximately 0.82 and N2 is approximately 112 milliseconds.
14. The apparatus according to claim 12, wherein N1 is approximately 1.0 and N2 is approximately 159 milliseconds.  
25
15. The apparatus according to claim 12, wherein PR is measured using a programmable pulse generator having an electrode in a right atrium and an electrode sensing signals from a left ventricle.
- 30 16. The apparatus according to claim 15, wherein a P-wave is detected when it reaches 20 percent of a maximum P-wave amplitude in the right atrium.

17. The apparatus according to claim 15, wherein R is detected at a peak of the R-wave.
18. The apparatus according to claim 1, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a micromanometer signaling an onset of ventricular pressure during systole.
19. The apparatus according to claim 18, wherein  $AVD_c$  is calculated from a linear equation:  $AVD_c = M1 (PY) - M2$ .
20. The apparatus according to claim 19, wherein M1 is approximately 0.96 and M2 is approximately 139 milliseconds.
21. The apparatus according to claim 19, wherein M1 is approximately 1.0 and M2 is approximately 150 milliseconds.
22. The apparatus according to claim 18, wherein PY is measured using a programmable pulse generator having an electrode in a right atrium and the micromanometer in a left ventricle.
23. The apparatus according to claim 22, wherein a P-wave is detected when it reaches 20 percent of a maximum P-wave amplitude in the right atrium.
24. The apparatus according to claim 1, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a cardiac phonogram signaling an onset of ventricular pressure during systole.
25. The apparatus according to claim 1, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from an accelerometer signaling an onset of ventricular pressure during systole.

26. The apparatus according to claim 1, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a Doppler recording signaling an onset of ventricular pressure during systole.
- 5 27. The apparatus according to claim 1, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a echo imager signaling an onset of ventricular pressure during systole.
28. A method, comprising:
- 10 measuring an interval between a first electrical event and a second electrical event, the first electrical event related to an atrial contraction in a first predictable time-dependent relationship and the second electrical event related to a ventricular pacing signal that is optimally timed for maximum  $LV+dp/dt$  in a second predictable time-dependent relationship, the measuring performed during a nonpaced systolic
- 15 cycle; and
- delivering a pacing pulse to a ventricle with a generated atrio-ventricular delay ( $AVD_c$ ) produced from a predetermined mapping of the relationship of the interval to an optimal atrio-ventricular delay for maximum  $LV+dp/dt$ ;
- wherein  $AVD_c$  provides an approximation of the optimal atrio-ventricular
- 20 delay for pacing the ventricle to provide maximum  $LV+dp/dt$ .
29. The method according to claim 28, wherein the first electrical event is a P-wave, the second electrical event is a beginning of a QRS complex ( $Q^*$ ), and the interval is between the P-wave and  $Q^*$  ( $PQ^*$ ).
- 25
30. The method according to claim 29, wherein  $AVD_c$  is calculated from a linear equation:  $AVD_c = K1 (PQ^*) - K2$ .
31. The method according to claim 30, wherein  $K1$  is approximately 0.94 and  $K2$
- 30 is approximately 55.7 milliseconds.
32. The method according to claim 30, wherein  $K1$  is approximately 1.0 and  $K2$  is approximately 67 milliseconds.

33. The method according to claim 30, wherein PQ\* is measured using a programmable pulse generator having an electrode in a right atrium and an electrode sensing signals from a left ventricle.
- 5 34. The method according to claim 33, comprising detecting a P-wave when it reaches 20 percent of a maximum P-wave amplitude in the right atrium.
35. The method according to claim 33, comprising detecting Q\* using a low pass filter.
- 10 36. The method according to claim 35, comprising detecting Q\* when a slope of a Q-wave reaches 2 percent of its maximum absolute value of the Q-wave slope.
37. The method according to claim 30, wherein PQ\* is measured using surface  
15 EKG.
38. The method according to claim 28, wherein the first electrical event is a P-wave, the second electrical event is a peak of an R-wave (R), and the interval is between the P-wave and R (PR).
- 20 39. The method according to claim 38, wherein  $AVD_c$  is calculated from a linear equation:  $AVD_c = N1 (PR) - N2$ .
40. The method according to claim 39, wherein N1 is approximately 0.82 and N2  
25 is approximately 112 milliseconds.
41. The method according to claim 39, wherein N1 is approximately 1.0 and N2 is approximately 159 milliseconds.
- 30 42. The method according to claim 38, wherein PR is measured using a programmable pulse generator having an electrode in a right atrium and an electrode sensing signals from a left ventricle.



43. The method according to claim 42, comprising detecting a P-wave when it reaches 20 percent of a maximum P-wave amplitude in the right atrium.
44. The method according to claim 42, comprising detecting R at a peak of the  
5 R-wave.
45. The method according to claim 28, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a micromanometer signaling an onset of ventricular pressure during systole.
- 10 46. The method according to claim 45, wherein  $AVD_c$  is calculated from a linear equation:  $AVD_c = M1 (PY) - M2$ .
47. The method according to claim 46, wherein M1 is approximately 0.96 and  
15 M2 is approximately 139 milliseconds.
48. The method according to claim 46, wherein M1 is approximately 1.0 and M2 is approximately 150 milliseconds.
- 20 49. The method according to claim 45, wherein PY is measured using a programmable pulse generator having an electrode in a right atrium and the micromanometer in a left ventricle.
50. The method according to claim 49, comprising detecting a P-wave when it  
25 reaches 20 percent of a maximum P-wave amplitude in the right atrium.
51. The method according to claim 28, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a cardiac phonogram signaling an onset of ventricular pressure during systole.
- 30 52. The method according to claim 28, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from an accelerometer signaling an onset of ventricular pressure during systole.

53. The method according to claim 28, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a Doppler recording signaling an onset of ventricular pressure during systole.
- 5 54. The method according to claim 28, wherein the first electrical event is a P-wave, the second electrical event is an electrical signal (Y) from a echo imager signaling an onset of ventricular pressure during systole.
55. A method, comprising:  
10 monitoring a signal representing ventricular mechanical activity;  
determining a ventricular mechanical event, Y, which has an approximately constant timing relationship to delivery of ventricular pacing that maximizes peak positive ventricular pressure change; and  
delivering a pacing pulse using a timing of event Y.
- 15 56. The method of claim 55, wherein the event relating to ventricular mechanical activity includes measuring a slope of ventricular pressure.
57. The method of claim 55, wherein the event has a standard deviation which is  
20 the lesser of 20 ms or 25% of the population mean.
58. A method, comprising:  
monitoring a signal representing ventricular electrical activity;  
determining a ventricular electrical event, Z, which has an approximately  
25 constant timing relationship to delivery of ventricular pacing that maximizes peak positive ventricular pressure change; and  
delivering a pacing pulse using a timing of event Z.
59. The method of claim 58, wherein the signal representing ventricular  
30 electrical activity comprises intracardiac electrogram recorded endocardially or epicardially from a ventricle.

60. The method of claim 58, wherein the signal representing ventricular electrical activity comprises 12-lead surface ECG.
61. The method of claim 58, wherein the event is a beginning of a QRS complex,  
5 Q\*.
62. The method of claim 58, wherein the event is a marker signal delivered by an external or implantable device.
- 10 63. A method, comprising:  
monitoring a signal representing atrial mechanical activity;  
determining an atrial mechanical event, X, which has a constant timing relationship to the peak of atrial systole; and  
delivering pacing pulse using the timing of event X.
- 15 64. A method, comprising:  
delivering a ventricular pacing pulse with an optimal atrio-ventricular delay time interval (AVDc) which is optimized to provide a maximum increase in LV +dp/dt (contractility) using the time interval, PY, between an atrial electrical event P  
20 and a ventricular mechanical event Y.
65. The method of claim 64, comprising:  
determining the optimal atrio-ventricular delay (AVDc), in milliseconds, as a function of the time interval, PY, in milliseconds;  
25 determining a model which approximates the optimal atrio-ventricular delay (AVDc) to provided an estimated AVDc; and  
delivering a ventricular pacing pulse to a next (new) patient to maximize the LV +dp/dt (contractility) using the estimated AVDc.
- 30 66. The method of claim 65, comprising:  
performing a linear regression (best line fit) between the time interval, PY, and the optimal atrio-ventricular delay (AVDc) determined experimentally; and

delivering a pacing signal using the estimated AVDc which is provided by  $M1(PY) - M2$ , where M1, and M2 are coefficients of the linear regression (best line fit).

- 5 67. The method of claim 66, where pacing is delivered to a left ventricle, and where the time interval PY is measured from a right atrial sensing marker, P, to the beginning of intrinsic LV pressure development, Y, which corresponds to the beginning of LV systole, M1 is approximately kk, M2 is approximately qq milliseconds, and the best line fit for the estimated AVDc is  $kkPY - qq$ .

10

68. The method of claim 65, comprising:

measuring the time difference, denoted as n, in milliseconds, between the time interval PY and the optimal atrio-ventricular delay (AVDc) determined experimentally;

15

- averaging this time difference n over the patient population; and delivering a pacing signal using the estimated AVDc which is provided by  $PY - na$ , where na is the mean of the time difference n.

69. The method of claim 65, where pacing is delivered to a left ventricle, and where the time interval PY is measured from a right atrial sensing marker, P, to the beginning of intrinsic LV pressure development, Y, which corresponds to the beginning of LV systole, na is approximately kk milliseconds, and the estimated AVDc is  $PY - kk$ .

25

70. A method, comprising:

filtering a signal representing ventricular electrical events to provide a filtered signal;

determining a portion of the filtered signal related to the Q-point; and

finding Q\* at a position where the slope of the filtered signal related to Q-

- 30 point is a predetermined ratio of the maximum slope of the filtered signal related to Q-point.

71. The method of claim 70, where the predetermined ratio is two (2) percent.

72. A method, comprising:  
selecting a cardiac reference event which repeats every cardiac cycle;  
selecting a cardiac variable event which changes as a function of a cardiac  
performance parameter, the cardiac performance parameter related to optimal atrio-  
5 ventricular delay;  
measuring an intrinsic time interval between the cardiac reference event and  
the cardiac variable event in an unpaced condition;  
determining an optimal atrio-ventricular delay for optimizing the cardiac  
performance parameter;  
10 collecting a plurality of pairs of intrinsic time intervals to optimal atrio-  
ventricular delays for a number of patients;  
producing a mathematical relationship between the intrinsic time interval and  
the optimal atrio-ventricular delays.
- 15 73. The method of claim 72, comprising generating pacing pulses using an  
estimated optimal atrio-ventricular delay produced from the mathematical  
relationship and a particular measured intrinsic time interval for a particular patient.
74. The method of claim 72, wherein the cardiac performance parameter is  
20 contractility.
75. The method of claim 72, wherein the cardiac performance parameter is  
maximum pulse pressure or stroke volume.
- 25 76. The method of claim 72, wherein the cardiac reference event is an electrical  
cardiac event.
77. The method of claim 72, wherein the cardiac reference event is a mechanical  
cardiac event.  
30
78. The method of claim 72, wherein the cardiac variable event is an electrical  
cardiac event.

79. The method of claim 72, wherein the cardiac variable event is a mechanical cardiac event.
80. The method of claim 72, comprising:
- 5       determining a second optimal atrio-ventricular delay for optimizing a second cardiac performance parameter;
- collecting a plurality of pairs of intrinsic time intervals to second optimal atrio-ventricular delays for a number of patients;
- producing a second mathematical relationship between the intrinsic time
- 10   interval, the optimal atrio-ventricular delays and the second optimal atrio-ventricular delays.
81. The method of claim 80, wherein the second mathematical relationship results in an optimal atrio-ventricular delay for optimizing the cardiac performance
- 15   parameter and the second cardiac performance parameter.
82. The method of claim 80, wherein the cardiac performance parameter is contractility and the second cardiac performance parameter is stroke volume.
- 20   83. The method of claim 82, wherein the mathematical relationship is:
- $AVDcs = K3 PRm - K4 \text{ milliseconds}$ .
84. The method of claim 83, wherein the mathematical relationship is:
- $AVDcs = 0.5 PRm - 15 \text{ milliseconds}$ .
- 25   85. The method of claims 80-84 wherein the atrio-ventricular delay is switchable for a number of different optimal cardiac performance parameters and combinations of cardiac performance parameters.
- 30   86. A programmable, implantable apparatus for generating pulses in any of the timing relationships of the foregoing claims 28-86.

1/18




FIG. 1

2/18




FIG. 2





FIG. 3





CONTRACTILITY (NOT TO SCALE)

FIG. 4A




FIG. 4B




FIG. 4C

4/18




FIG. 4D




FIG. 4E

5/18



FIG. 5A

6/18




FIG. 5B

7/18




FIG. 5C

8/18




FIG. 5D

9/18.




FIG. 5E




FIG. 5F



11/18




FIG. 6

12/18




FIG. 7

13/18




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D

14/18




FIG. 9

15/18




FIG. 10

16/18




FIG. 11A




FIG. 11B

17/18




FIG. 12A




FIG. 12B

18/18




FIG. 13



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10142

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61N1/368

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 690 689 A (SHOLDER JASON A) 25 November 1997 (1997-11-25) abstract column 5, line 39 - line 50 column 17, line 43 - column 18, line 13 claim 19; figures	1,11,12, 15
A	---	13,14, 16,17
A	US 5 700 283 A (SALO RODNEY W) 23 December 1997 (1997-12-23) abstract column 3, line 20 - column 5, line 8 figures	1,18,25
A	---	
A	US 5 334 222 A (SALO RODNEY W ET AL) 2 August 1994 (1994-08-02) the whole document	1,18,25
	---	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 August 1999

Date of mailing of the international search report

23/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Ferrigno, A

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/10142

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 554 177 A (KIEVAL ROBERT S ET AL) 10 September 1996 (1996-09-10) abstract; figures ---	1,24,26
A	US 5 318 595 A (BREYER BRANKO ET AL) 7 June 1994 (1994-06-07) the whole document ---	1,27
A	EP 0 474 958 A (FEREK PETRIC BOZIDAR ;BREYER BRANCO (YU)) 18 March 1992 (1992-03-18) abstract; figures -----	1,27

# INTERNATIONAL SEARCH REPORT

I. International application No.

PCT/US 99/ 10142

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28-85  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: 86  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/ 210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: 86

The subject-matter of claim 86 is not defined: it is not clear which feature should be searched.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 86

The subject-matter of claim 86 is not defined: it is not clear which feature should be searched.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/10142

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5690689 A	25-11-1997	US 5340361 A AU 661954 B AU 5062993 A EP 0597728 A JP 7016303 A	23-08-1994 10-08-1995 26-05-1994 18-05-1994 20-01-1995
US 5700283 A	23-12-1997	NONE	
US 5334222 A	02-08-1994	US 5584868 A	17-12-1996
US 5554177 A	10-09-1996	NONE	
US 5318595 A	07-06-1994	US 5316001 A DE 69122015 D DE 69122015 T EP 0474957 A EP 0474958 A US 5243976 A	31-05-1994 17-10-1996 17-04-1997 18-03-1992 18-03-1992 14-09-1993
EP 0474958 A	18-03-1992	DE 69122015 D DE 69122015 T EP 0474957 A US 5316001 A US 5243976 A US 5318595 A	17-10-1996 17-04-1997 18-03-1992 31-05-1994 14-09-1993 07-06-1994